Xvivo Perfusion AB (publ)
XVIPY
Other OTC7.13
USD
+0.59
- -
ISIN
US98390P1066
CUSIP
98390P106
Return %
Stock
S&P500
1Y
25.07
17.85
3Y
14.24
64.56
5Y
78.22
69.89
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Christoffer Rosenblad
- Full Time Employees
- 170
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- MAessans gata 10 Gothenburg Sweden 412 51
- IPO Date
- Sep 23, 2022
- Website
- xvivoperfusion.com
- Similar Companies
- Business
- Xvivo Perfusion AB (publ) is a specialized medical technology innovator, dedicated to advancing solutions for preserving and perfusing organs, tissues, and cells destined for transplantation across global markets, including Sweden, the United States, North and South America, Europe, the Middle East, Africa, and the Asia Pacific region. The company is committed to enhancing the viability and assessment of donor organs outside the body. Their comprehensive product portfolio spans multiple organ areas. For lung transplantation, they provide the XVIVO System (XPS), an integrated platform designed for normothermic ex vivo lung perfusion (EVLP), alongside the XPS Disposable Lung Kit, which contains essential sterile components for the procedure. Also offered is STEEN Solution, a specialized buffered solution crucial for perfusing isolated donor lungs during EVLP, and Perfadex Plus, an extracellular, low-potassium, dextran-based electrolyte solution recognized as a gold standard for flushing, cold static storage, and transport of isolated lungs. Additionally, the XVIVO Organ Chamber serves as a sterile, single-use receptacle for temporary lung storage, and the XVIVO Lung Cannula Set connects donor lungs to perfusion systems. In the abdominal segment, Xvivo offers Kidney Assist Transport, a portable device enabling hypothermic pulsatile perfusion of donor kidneys with an oxygenated solution for up to 24 hours. For liver transplantation, Liver Assist provides clinicians with various perfusion protocols, establishing itself as a leading technology in Europe. The company’s innovative approach extends to heart preservation with the XVIVO Heart Assist Transport device, which recently completed US clinical study enrollment and is moving towards a European launch. Beyond products, Xvivo also delivers crucial services, including organ recovery by experienced teams and an advanced communication platform for transplant logistics. Founded in 1998 and headquartered in Mölndal, Sweden, Xvivo Perfusion AB (publ) leverages its machine perfusion technologies to improve transplant outcomes, expand the donor pool, and address the critical global shortage of organs, offering solutions for all four major organs. Recent developments include FDA Breakthrough Device Designation for their liver technology, with a US clinical trial expected to begin in Q3 2025.
Xvivo Perfusion AB (publ) (XVIPY) Q2 2026 Earnings Call Transcript
Bulletin from Annual General Meeting in XVIVO Perfusion AB (publ)
Xvivo Perfusion AB (publ) (XVIPY) Q1 2026 Earnings Call Transcript
Notice To Attend the Annual General Meeting in XVIVO Perfusion Ab (Publ)
The Nomination Committee of XVIVO Perfusion AB (publ) Proposes Emil Billbäck and Anne-Karen Hunt as New Members of the Board of Directors
Xvivo Perfusion AB (publ) (XVIPY) Q4 2025 Earnings Call Transcript
Xvivo Perfusion AB (publ) (XVIPY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript